These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18296421)

  • 1. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
    Untch M; Gelber RD; Jackisch C; Procter M; Baselga J; Bell R; Cameron D; Bari M; Smith I; Leyland-Jones B; de Azambuja E; Wermuth P; Khasanov R; Feng-Yi F; Constantin C; Mayordomo JI; Su CH; Yu SY; Lluch A; Senkus-Konefka E; Price C; Haslbauer F; Suarez Sahui T; Srimuninnimit V; Colleoni M; Coates AS; Piccart-Gebhart MJ; Goldhirsch A;
    Ann Oncol; 2008 Jun; 19(6):1090-6. PubMed ID: 18296421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
    J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sánchez Rovira P; Piccart-Gebhart MJ;
    Lancet; 2007 Jan; 369(9555):29-36. PubMed ID: 17208639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
    Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
    Goldhirsch A; Gelber RD; Piccart-Gebhart MJ; de Azambuja E; Procter M; Suter TM; Jackisch C; Cameron D; Weber HA; Heinzmann D; Dal Lago L; McFadden E; Dowsett M; Untch M; Gianni L; Bell R; Köhne CH; Vindevoghel A; Andersson M; Brunt AM; Otero-Reyes D; Song S; Smith I; Leyland-Jones B; Baselga J;
    Lancet; 2013 Sep; 382(9897):1021-8. PubMed ID: 23871490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
    Kim MM; Dawood S; Allen P; Sahin AA; Woodward WA; Smith BD; Strom EA; Hunt KK; Meric-Bernstam F; Gonzalez-Angulo AM; Buchholz TA
    Cancer; 2012 Oct; 118(20):4936-43. PubMed ID: 22511276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
    Partridge AH; Gelber S; Piccart-Gebhart MJ; Focant F; Scullion M; Holmes E; Winer EP; Gelber RD
    J Clin Oncol; 2013 Jul; 31(21):2692-8. PubMed ID: 23752109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
    Zabaglo L; Stoss O; Rüschoff J; Zielinski D; Salter J; Arfi M; Bradbury I; Dafni U; Piccart-Gebhart M; Procter M; Dowsett M;
    Ann Oncol; 2013 Nov; 24(11):2761-6. PubMed ID: 23894039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
    O'Sullivan CC; Bradbury I; Campbell C; Spielmann M; Perez EA; Joensuu H; Costantino JP; Delaloge S; Rastogi P; Zardavas D; Ballman KV; Holmes E; de Azambuja E; Piccart-Gebhart M; Zujewski JA; Gelber RD
    J Clin Oncol; 2015 Aug; 33(24):2600-8. PubMed ID: 26101239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
    Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
    Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
    Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC; Holmes E; de Azambuja E; Metzger-Filho O; Hogge L; Scullion M; Láng I; Wardley A; Lichinitser M; Sanchez RI; Müller V; Dodwell D; Gelber RD; Piccart-Gebhart MJ; Cameron D
    Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
    Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
    J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
    Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
    Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.